The shutdown of the US Federal Government has a wide scope of consequences, all negative. However, some repercussions are more serious than others. One very serious side effect of the shutdown is that upwards of 200 patients per week are being turned away from clinical trials administered and overseen by various federal agencies including the […]
Stem cell research is exciting on many levels and provides real hope for treating an assortment of serious diseases and injuries in the future, but another potential positive of stem cells such as iPS cells is their use in producing modeling human tissues and organs to model diseases. A third positive, but often overlooked potential
Stem Cells Will Reduce Need for Research Animals Read More »
New ISSCR President, Dr. Janet Rossant, kindly agreed to do an interview with me focused on the future of ISSCR, her plans for her tenure, and some key issues in the field. Dr. Rossant is Chief of Research at The Hospital for Sick Children in Toronto. 1. The stem cell arena is a very rapidly changing one
Celebrities such as Kim Kardashian are reportedly getting so-called vampire facials. Why put yourself through that? Perhaps because stem cells and other material inside the processed blood is supposed to make them younger? Yes, that is Kim above (photo from Kim Kardashian on Instagram) with her face smeared with blood, but not just ordinary Kardashian
Kim Kardashian vampire facials: stem cells in there? Read More »
The poll I put up asking people their #1 top priority for FDA reform drew relatively big numbers of respondents. Speeding up clinical trials was clearly way out in front at #1. Expanding compassionate use was #2. These were followed by changing policy to no longer define lab-grown stem cells as drugs and FDA being
Results of FDA Reform Poll: speed up clinical trials & expand compassionate use Read More »
It is always exciting when a biomedical technology as revolutionary as iPS cells is on the cusp of being used in patients for the first time. In the last few days stories have reported about how a proposed clinical trial based on iPS cells has completed several regulatory steps and is closer to starting. This
The Korean-based stem cell biotech, RNL Bio, which also does business in the U.S. as RNL Bio and Human Biostar Inc, reportedly (seems to be a press release, PR) has filed an investigational new drug (IND) application with the Korean FDA (KFDA). The purpose of the application is to test the efficacy of autologous adult stem cells
This is the first in a new series of posts I’m doing in lessons I’ve learned from the ever-increasing number of patients who contact me directly or are readers of this blog who make great comments. Today’s post is focused on the lack of availability of and exclusions of the vast majority of patients from
Lessons from patients: stem cell clinical trials unlikely option for most patients Read More »
One of the most exciting types of stem cells are mesenchymal stem cells or MSCs. Although there is some debate about these cells (e.g. I once heard Irv Weissman say at a meeting he wasn’t sure they really existed as such), a consensus would seem to be that they have great potential medical potential. Perhaps
Mapping global trends in MSC & stem cell clinical trials: unexpected findings Read More »
What’s the big deal about unproven stem cell treatments, patients often ask me. Why should patients avoid these? Because paradoxically such treatments, intended to cure disease, can have devastating negative consequences for your health. I’m doing an eight-part series, “Eight simple reasons not to get a stem cell treatment”. The first two blog posts were